Openbookopenbook
Equity
Astellas Pharma Inc(ALPMY)
USD --+0.00%
Reward75High
Risk17Low
📊75%Data
3.6% dividend yield · Revenue growing 21% YoY
ALPMY
+0.0 · +0.00%
USD · PINK
Astellas Pharma Inc | Healthcare
Quality Compounder
Market Cap:25.44Bn
ℹ️
Reward Rating
75
High
Top 10% (model universe)
75% data coverage
ℹ️
Risk Rating
17
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ALPMY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $19.00.

What is Astellas Pharma Inc?

manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally.

ALPMY · Verdict

Strong reward · low risk

ALPMY scores well on valuation and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

ALPMY · Verdict

What’s working & what to watch

Strengths 6

  • Valuation100/100

    P/E 12.8× · PEG 0.48

  • Volatility95/100

    Top decile vs peers

  • Profitability87/100

    14% net margin · 17% ROE

  • Cash flow87/100

    24% free-cash-flow margin

  • Growth74/100

    Rev +14.3% CAGR · earnings +46.3%

  • Balance sheet72/100

    Interest covered 16.0×

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Astellas Pharma Inc?

manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 25.44B, and a P/E ratio of 13.9x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: High (75)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap25.44B
P/E Ratio13.9216
Dividend Yield3.58%
52 Week High16.88
52 Week Low8.6144
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding2B
No. of Employees13,643
IndustryDrug Manufacturers - General
ExchangePINK
Beta0.147
CurrencyUSD
Websitewww.astellas.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.